Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward



  • Oklahoma enacts opioid prescribing restrictions

    by
    • Optum Workers' Comp
    | May 08, 2018
    Tag Icon
    Workers' Compensation, Pain Management, Opioids, Formularies
    Oklahoma Senate Bill 1446, effective November 1, 2018, limits opioid pain medication to a 7 day-supply.


  • North Carolina Workers’ Comp. Opioid Treatment Rules Approved

    by
    • Optum Workers' Comp
    | May 01, 2018
    Tag Icon
    Workers' Compensation, Pain Management, Opioids, Formularies
    North Carolina’s Rules Review Commission (RRC) recently approved the opioid treatment rules submitted by the North Carolina Industrial Commission. The new rules address requirements for the use of opioid analgesics, related prescriptions and pain management treatment for injured workers in both the acute and chronic phases.


  • Pennsylvania Legislature passes workers’ compensation drug formulary bill

    by
    • Optum Workers' Comp
    | Apr 20, 2018
    Tag Icon
    evidence-based prescription formulary, formulary, Workers' Compensation, State Formulary, Drug Formulary, Formularies
    On April 16, 2018, the Pennsylvania General Assembly took a step forward in requiring utilization of a drug formulary for workers’ compensation claims in the state. Senate Bill 936, originally failed to pass the House in February on a tie vote of 98-98, however the House approved it this week by a slim margin of 101-92. The bill now heads to Governor Tom Wolf’s desk for his action.


  • Texas adopts closed drug formulary rule changes to require preauthorization on compounded medications

    by
    • Optum Workers' Comp
    | Apr 18, 2018
    Tag Icon
    Drug Formulary, Formularies, Compounded Medications
    Effective July 1, 2018, the Texas Division of Workers’ Compensation (TDWC) formally enacts changes to its Closed Drug Formulary. The changes enforce new requirements for preauthorization and prospective review of compounded medications.


  • National Prescription Drug Take Back Day Slated for April 28

    by
    • Optum Workers' Comp
    | Apr 17, 2018
    Tag Icon
    Overdose, DEA
    Saturday, April 28, from 10 a.m. to 2 p.m., is National Prescription Drug Take Back Day sponsored by the U.S. Drug Enforcement Administration (DEA). The purpose of National Prescription Drug Take Back Day is to provide a safe, convenient, and responsible way to dispose of prescription medications that are unwanted, unused, or expired, while also educating the public on the potential abuse of medications.


  • Arizona enacts enhanced opioid controls for workers’ compensation claims

    by
    • Optum Workers' Comp
    | Apr 11, 2018
    Tag Icon
    Drug Utilization Review, Workers' Compensation, Opioids
    On March 29, 2018 Arizona Governor Ducey signed into law Senate Bill 1111, to better control opioid utilization in the Arizona workers’ compensation system. SB 1111 applies prescribing restrictions for doctors who are providing opioid analgesic treatment specifically to injured workers. The Bill also enhances opioid reporting and requires doctors to provide the appropriate justification as to why opioids are necessary to treat a work-related injury.


  • FDA advisory committee recommends approval of lofexidine for opioid withdrawal symptoms

    by
    • Optum Workers' Comp
    | Apr 06, 2018
    Tag Icon
    Workers' Compensation, Opioids, FDA
    An advisory committee of the U.S. Food and Drug Administration (FDA) voted to approve a non-opioid, lofexidine hydrochloride, to alleviate the symptoms of abrupt opioid withdrawal. Lofexidine, an alpha-2 adrenergic agonist that works by reducing the release of norepinephrine, is similar to clonidine, which has been used off-label for the management of opioid withdrawal symptoms. According to this report, lofexidine has been found to be safe and effective in reducing symptoms of nausea, vomiting, anxiety, diarrhea and the overall feeling of sickness during withdrawal. Lofexidine has been marketed in the United Kingdom (UK) as BritLofex since 1992 to relieve symptoms in patients undergoing opioid detoxification.



Stay informed by receiving latest updates

Do you have a question about a blog post?

See more insights